MHC
MRVI icon

May Hill Capital’s Maravai LifeSciences MRVI Stock Holding History

May Hill Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,462
Closed -$35.8K – 208
2025
Q3 		$35.8K Sell
12,462
-10,048
-45% -$25.7K 0.01% 190
2025
Q2 		$54.2K Buy
+22,510
New +$47.3K 0.02% 191

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

May Hill Capital's MRVI Position: Q4 2025 in Review

May Hill Capital sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 12,462 shares — an estimated $35.8K sold.

May Hill Capital first reported a position in MRVI in Q2 2025 and held it in 2 quarters. The position peaked at $54.2K in Q2 2025. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • May Hill Capital reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
  • May Hill Capital sold 12,462 Maravai LifeSciences shares in Q4 2025, an estimated $35.8K.
  • May Hill Capital first reported a position in Maravai LifeSciences in Q2 2025 and held it in 2 quarters.
  • May Hill Capital's Maravai LifeSciences position peaked at $54.2K in Q2 2025.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on May Hill Capital's 13F filing for Q4 2025, filed 5 Feb 2026.